Jane Street Group, LLC Fate Therapeutics Inc Transaction History

Jane Street Group, LLC

  • $384 Billion
  • Q1 2025

A detailed history of Jane Street Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 63,691 shares of FATE stock, worth $79,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,691
Previous 63,691 -0.0%
Holding current value
$79,613
Previous $50,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
BUY
$0.79 - $1.87 $25,999 - $61,543
32,911 Added 106.92%
63,691 $50,000
Q4 2024

Feb 14, 2025
SELL
$1.61 - $3.35 $188,518 - $392,258
-117,092 Reduced 79.18%
30,780 $50,000
Q3 2024

Nov 14, 2024
SELL
$3.12 - $5.57 $217,985 - $389,159
-69,867 Reduced 32.09%
147,872 $517,000
Q2 2024

Aug 14, 2024
BUY
$3.26 - $7.08 $75,240 - $163,406
23,080 Added 11.86%
217,739 $714,000
Q1 2024

May 15, 2024
SELL
$3.54 - $8.35 $1.83 Million - $4.31 Million
-516,628 Reduced 72.63%
194,659 $1.43 Million
Q4 2023

Feb 14, 2024
SELL
$1.65 - $3.94 $21,426 - $51,164
-12,986 Reduced 1.79%
711,287 $2.66 Million
Q3 2023

Nov 14, 2023
BUY
$2.02 - $5.04 $533,261 - $1.33 Million
263,991 Added 57.35%
724,273 $1.54 Million
Q2 2023

Aug 14, 2023
BUY
$4.76 - $6.59 $1.74 Million - $2.41 Million
365,254 Added 384.36%
460,282 $2.19 Million
Q1 2023

May 15, 2023
SELL
$4.24 - $11.12 $254,056 - $666,299
-59,919 Reduced 38.67%
95,028 $541,000
Q4 2022

Feb 14, 2023
BUY
$9.86 - $23.83 $1.41 Million - $3.41 Million
143,023 Added 1199.45%
154,947 $1.56 Million
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $216,101 - $370,372
-10,271 Reduced 46.28%
11,924 $267,000
Q2 2022

Aug 16, 2022
SELL
$17.78 - $42.39 $54,051 - $128,865
-3,040 Reduced 12.05%
22,195 $550,000
Q4 2021

Feb 15, 2022
BUY
$47.84 - $64.34 $462,660 - $622,232
9,671 Added 62.14%
25,235 $1.48 Million
Q3 2021

Nov 16, 2021
SELL
$59.27 - $95.73 $54,054 - $87,305
-912 Reduced 5.54%
15,564 $922,000
Q2 2021

Aug 16, 2021
SELL
$67.25 - $92.52 $1.67 Million - $2.29 Million
-24,798 Reduced 60.08%
16,476 $1.43 Million
Q1 2021

May 18, 2021
SELL
$72.16 - $117.4 $1.6 Million - $2.61 Million
-22,214 Reduced 34.99%
41,274 $3.4 Million
Q4 2020

Feb 17, 2021
BUY
$38.09 - $100.95 $758,486 - $2.01 Million
19,913 Added 45.7%
63,488 $5.77 Million
Q3 2020

Nov 17, 2020
BUY
$30.41 - $40.5 $1.08 Million - $1.44 Million
35,593 Added 445.92%
43,575 $1.74 Million
Q2 2020

Aug 17, 2020
SELL
$20.21 - $35.23 $62,428 - $108,825
-3,089 Reduced 27.9%
7,982 $274,000
Q1 2020

May 15, 2020
BUY
$17.28 - $31.88 $191,306 - $352,943
11,071 New
11,071 $246,000
Q4 2019

Feb 14, 2020
SELL
$13.39 - $20.73 $208,375 - $322,600
-15,562 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$15.47 - $22.5 $4,950 - $7,200
320 Added 2.1%
15,562 $242,000
Q2 2019

Aug 15, 2019
BUY
$15.61 - $20.44 $237,927 - $311,546
15,242 New
15,242 $309,000
Q1 2019

May 16, 2019
SELL
$13.15 - $18.71 $179,576 - $255,503
-13,656 Closed
0 $0
Q4 2018

Feb 15, 2019
BUY
$11.48 - $16.98 $40,512 - $59,922
3,529 Added 34.85%
13,656 $175,000
Q3 2018

Nov 14, 2018
SELL
$8.75 - $16.29 $752 - $1,400
-86 Reduced 0.84%
10,127 $165,000
Q2 2018

Aug 15, 2018
BUY
$9.16 - $13.48 $93,551 - $137,671
10,213 New
10,213 $116,000
Q4 2017

Feb 15, 2018
SELL
$3.94 - $6.64 $44,490 - $74,978
-11,292 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$2.6 - $4.31 $29,359 - $48,668
11,292
11,292 $45,000

Others Institutions Holding FATE

# of Institutions
144
Shares Held
96M
Call Options Held
56.7K
Put Options Held
5.4K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $121M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email